AI-Powered Skin Cancer Detection
Assess Skin Cancer Risk
DermaSensor combines advanced spectroscopy and machine learning algorithms to help physicians evaluate skin lesions with a quick, non-invasive, and objective test.
How Does DermaSensor Work?
The DermaSensor device is based on a unique optical spectroscopy technology known as elastic scattering spectroscopy (ESS), which analyzes how light interacts with cellular structures beneath the skin. When the device assesses a lesion, it emits pulses of light and captures spectral signals that reflect microscopic features, such as cell density and nucleus size.
These spectral signals are analyzed by a proprietary AI algorithm. Within seconds, the device provides an objective test result to help providers determine whether a lesion requires further investigation.
-
Elastic Scattering Spectroscopy (ESS) Tissue Analysis
Book a Device DemoDermaSensor uses ESS technology to analyze microscopic tissue characteristics beneath the skin surface. By measuring how light reflects off cellular structures, the technology captures optical signals associated with histopathological features of malignancy, such as nucleus size, the presence of condensed chromatin, and melanocyte density. No imaging, biopsies, or invasive methods are required for this analysis.
-
AI Trained on Clinical Data
Book a Device DemoDermaSensor’s proprietary machine learning algorithm was developed and validated using over 20,000 scans from more than 4,000 malignant and benign lesions collected during clinical studies. By comparing each lesion’s spectral signature to patterns linked to known malignancies, the algorithm produces an objective result to support clinicians’ management decisions.
-
Rapid and Repeatable Spectral Measurements
Book a Device DemoDuring a device scan, DermaSensor’s xenon lamp captures five spectral recordings from different areas of a lesion, similar to how pathologists assess different areas of tissue under microscope. Each recording samples a small volume of tissue and measures light reflectance across 47 wavelengths, providing a detailed spectral signature that identifies patterns associated with benign or malignant lesions.
-
Objective Immediate Results
Book a Device DemoOnce the recordings are complete, the algorithm analyzes the spectral data to deliver a binary result of “Monitor” or “Investigate Further.” If the result is “Investigate Further,” the device provides a spectral score indicating similarity to malignant lesions on a scale of 1 to 10, with higher values indicating greater similarity to malignant lesions.
96% Sensitivity for Detecting Skin Cancers
In clinical studies, DermaSensor demonstrated 96% sensitivity for detecting melanoma, basal cell carcinoma, and squamous cell carcinoma, helping providers identify suspicious lesions that may require dermatology referral or further evaluation.
-
For Private Practices
Primary care and independent practices use DermaSensor to quickly evaluate concerning skin lesions during routine visits, provide patients with immediate answers, and aid clinicians in making informed referral decisions.
Learn More -
For Health Systems
Health systems can seamlessly integrate the device into primary care settings to increase skin cancer exams, expand preventive care options, and improve referral triage and prioritization between primary care and dermatology.
Learn More
80-0009.16
